DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Riociguat

Phase Two

Phase Two

Therapeutic Approach

Restore CFTR Function

Riociguat is a novel therapy that stimulates sGC, an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). Preclinical data has shown evidence that riociguat can result in improved function of the CFTR protein as a chloride channel, moving salt and fluids in and out of cells.

Status

 A Phase 2 trial is underway in adults who have two copies of the F508del mutation.

Sponsor

This program is sponsored by Bayer and is being conducted within CFFT's Therapeutics Development Network.

Contact us about Riociguat >